Physician profile
Thomas B Sneed
NPI 1053317941
$873.71
in general payments reported to CMS, 2019-2025
12 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2021: $23.42 · 2022: $23.80 · 2023: $18.06 · 2024: $427 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $297 · Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $296.60 |
| Food and Beverage | $262.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $212.12 | 2024 | |
| Abbvie INC. | $194.99 | 2019 | |
| Trisalus Life Sciences, INC. | $137.49 | 2024 | Trinav Infusion System |
| Intuitive Surgical, INC. | $76.92 | 2024 | |
| Seagen INC. | $71.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Gilead Sciences, INC. | $28.73 | 2021-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $23.80 | 2022 | |
| Sumitomo Pharma America, INC. | $18.06 | 2023 | Orgovyx |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Celgene Corporation | $13.63 | 2025 | Opdivo |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sneed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.